Stock listing
NASDAQ:AVIR Atea Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Atea Pharmaceuticals, Inc.
Follow Atea Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:AVIR
$3.96 USD -0.03 (-0.8%)
Close on Nov 20, 2026
- Day range
- $3.80 – $4.09 USDNov 20, 2026
- Volume
- 416,457 sharesNov 20, 2026
- Market cap
- $317.6M USDAt the close on Nov 20, 2026 · price × 80.20M shares outstanding
- 52-week range
- $2.93 – $6.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.38M USDMedian day 279,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AVIR · Home | $3.96 USD | -0.03 (-0.8%) | 416,457 | $3.88 | $4.09 | $3.80 | $3.99 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AVIR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.96 | -0.03 | -0.8% | $3.88 | $4.09 | $3.80 | 416,457 | |
| $3.99 | +0.03 | +0.8% | $3.93 | $4.03 | $3.87 | 342,249 | |
| $3.96 | -0.16 | -3.9% | $4.11 | $4.18 | $3.85 | 448,459 | |
| $4.12 | -0.18 | -4.2% | $4.33 | $4.365 | $4.10 | 310,527 | |
| $4.30 | +0.09 | +2.1% | $4.25 | $4.35 | $4.10 | 302,651 | |
| $4.21 | -0.01 | -0.2% | $4.17 | $4.28 | $4.09 | 243,885 | |
| $4.22 | +0.02 | +0.5% | $4.22 | $4.34 | $4.04 | 320,528 | |
| $4.20 | -0.21 | -4.8% | $4.40 | $4.44 | $4.16 | 301,493 | |
| $4.41 | +0.10 | +2.3% | $4.35 | $4.475 | $4.315 | 244,167 | |
| $4.31 | +0.09 | +2.1% | $4.21 | $4.34 | $4.12 | 199,472 | |
| $4.22 | -0.24 | -5.4% | $4.48 | $4.49 | $4.19 | 298,410 | |
| $4.46 | +0.29 | +7.0% | $4.29 | $4.49 | $4.24 | 268,893 | |
| $4.17 | +0.07 | +1.7% | $4.14 | $4.33 | $4.105 | 391,257 | |
| $4.10 | -0.01 | -0.2% | $4.15 | $4.24 | $3.945 | 330,293 | |
| $4.11 | -0.20 | -4.6% | $4.30 | $4.32 | $4.07 | 349,862 | |
| $4.31 | +0.04 | +0.9% | $4.30 | $4.50 | $4.26 | 280,900 | |
| $4.27 | +0.10 | +2.4% | $4.15 | $4.27 | $4.14 | 328,400 | |
| $4.17 | +0.01 | +0.2% | $4.14 | $4.29 | $4.05 | 245,200 | |
| $4.16 | +0.12 | +3.0% | $4.04 | $4.24 | $3.94 | 251,100 | |
| $4.04 | -0.01 | -0.2% | $4.03 | $4.11 | $3.93 | 245,400 | |
| $4.05 | -0.03 | -0.7% | $4.08 | $4.17 | $4.02 | 318,800 | |
| $4.08 | -0.385 | -8.6% | $4.47 | $4.47 | $4.05 | 465,200 | |
| $4.465 | +0.075 | +1.7% | $4.34 | $4.58 | $4.315 | 288,800 | |
| $4.39 | +0.07 | +1.6% | $4.34 | $4.42 | $4.17 | 390,000 | |
| $4.32 | -0.21 | -4.6% | $4.54 | $4.55 | $4.30 | 345,800 | |
| $4.53 | -0.10 | -2.2% | $4.64 | $4.805 | $4.48 | 319,400 | |
| $4.63 | -0.35 | -7.0% | $4.92 | $4.92 | $4.60 | 414,500 | |
| $4.98 | -0.05 | -1.0% | $5.03 | $5.04 | $4.87 | 303,200 | |
| $5.03 | -0.12 | -2.3% | $5.13 | $5.20 | $5.03 | 190,700 | |
| $5.15 | -0.005 | -0.1% | $5.15 | $5.23 | $5.09 | 158,000 | |
| $5.155 | +0.145 | +2.9% | $4.98 | $5.23 | $4.91 | 350,900 | |
| $5.01 | -0.06 | -1.2% | $5.02 | $5.23 | $4.99 | 264,800 | |
| $5.07 | -0.06 | -1.2% | $5.16 | $5.19 | $4.98 | 229,400 | |
| $5.13 | 0.00 | 0.0% | $5.12 | $5.18 | $4.945 | 293,600 | |
| $5.13 | +0.03 | +0.6% | $5.16 | $5.215 | $5.05 | 253,300 | |
| $5.10 | -0.11 | -2.1% | $5.16 | $5.20 | $4.93 | 408,700 | |
| $5.21 | +0.03 | +0.6% | $5.20 | $5.29 | $5.14 | 296,300 | |
| $5.18 | -0.02 | -0.4% | $5.20 | $5.23 | $5.08 | 298,300 | |
| $5.20 | +0.03 | +0.6% | $5.15 | $5.30 | $5.10 | 238,400 | |
| $5.17 | 0.00 | 0.0% | $5.16 | $5.21 | $5.04 | 280,700 | |
| $5.17 | -0.11 | -2.1% | $5.28 | $5.305 | $5.14 | 228,800 | |
| $5.28 | -0.36 | -6.4% | $5.60 | $5.60 | $5.25 | 232,300 | |
| $5.64 | +0.21 | +3.9% | $5.46 | $5.655 | $5.38 | 237,500 | |
| $5.43 | +0.10 | +1.9% | $5.36 | $5.52 | $5.325 | 440,100 | |
| $5.33 | +0.07 | +1.3% | $5.21 | $5.37 | $5.17 | 600,400 | |
| $5.26 | +0.11 | +2.1% | $5.21 | $5.33 | $5.20 | 279,400 | |
| $5.15 | -0.08 | -1.5% | $5.23 | $5.33 | $5.15 | 274,200 | |
| $5.23 | -0.09 | -1.7% | $5.30 | $5.30 | $5.12 | 224,300 | |
| $5.32 | +0.01 | +0.2% | $5.31 | $5.455 | $5.25 | 272,800 | |
| $5.31 | +0.13 | +2.5% | $5.23 | $5.41 | $5.18 | 489,500 | |
| $5.18 | -0.09 | -1.7% | $5.22 | $5.30 | $5.17 | 251,100 | |
| $5.27 | -0.41 | -7.2% | $5.64 | $5.66 | $5.24 | 430,800 | |
| $5.68 | -0.15 | -2.6% | $5.80 | $5.85 | $5.635 | 216,600 | |
| $5.83 | +0.01 | +0.2% | $5.77 | $5.90 | $5.76 | 199,100 | |
| $5.82 | +0.12 | +2.1% | $5.70 | $5.84 | $5.63 | 198,500 | |
| $5.70 | +0.21 | +3.8% | $5.51 | $5.73 | $5.51 | 289,900 | |
| $5.49 | +0.14 | +2.6% | $5.31 | $5.51 | $5.31 | 253,300 | |
| $5.35 | -0.01 | -0.2% | $5.36 | $5.41 | $5.31 | 198,400 | |
| $5.36 | -0.09 | -1.7% | $5.48 | $5.51 | $5.29 | 144,700 | |
| $5.45 | -0.06 | -1.1% | $5.48 | $5.59 | $5.41 | 102,900 | |
| $5.51 | +0.08 | +1.5% | $5.43 | $5.59 | $5.30 | 214,100 | |
| $5.43 | -0.08 | -1.5% | $5.51 | $5.62 | $5.39 | 198,064 | |
| $5.51 | +0.08 | +1.5% | $5.385 | $5.53 | $5.25 | 100,100 | |
| $5.43 | +0.07 | +1.3% | $5.40 | $5.64 | $5.31 | 209,900 | |
| $5.36 | -0.23 | -4.1% | $5.52 | $5.545 | $5.35 | 214,300 |
- Ticker
- NASDAQ:AVIR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest earnings call · Aug 12, 2026
Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Aug 12, 2026
Q2 2026 Earnings Presentation
Earnings · 31 slides
Latest news
Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 9, 2026
Closed $4.20 (-4.8%) on Nov 10, 2026
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
Nov 9, 2026
Closed $4.41 (+2.3%) on Nov 9, 2026
Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026
Nov 2, 2026
Closed $4.17 (+1.7%) on Nov 3, 2026
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Sep 8, 2026
Closed $5.68 (-2.6%) on Sep 8, 2026
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 12, 2026
Closed $5.07 (+0.2%) on Aug 13, 2026
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
Aug 5, 2026
Closed $4.75 (+1.1%) on Aug 5, 2026
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Jul 28, 2026
Closed $4.51 (-6.4%) on Jul 28, 2026
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Jul 14, 2026
Closed $4.70 (-0.8%) on Jul 14, 2026
Atea Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 107 in all · newest Nov 9, 2026 · oldest 2020
- Calls
- 19 calls with a replay · 19 with a transcript · latest Aug 12, 2026
- Decks
- 12 decks · latest Aug 12, 2026
Where Atea Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AVIR · Home listing · This page | NASDAQ | United States | USD |
| BOATS:AVIR | BOATS | United States | USD |
Valuation
Price/book 1.8× against a median of 2.5×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $126.6M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.8×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.86
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. · NASDAQ:AVIR | US$317.6M | US$126.6M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 0.86 |
| Lyell Immunopharma, Inc. · NASDAQ:LYEL | US$339.3M | US$196.5M | n/a | 13,099× | n/a | 1.8× | n/a | 0.2× | 1.51 |
| Avacta Group PLC · LSE:AVCT | US$337.8M | US$337.2M | n/a | 2,281× | n/a | 68.5× | n/a | 5.3× | n/a |
| Inovio Pharmaceuticals, Inc. · NASDAQ:INO | US$329.7M | US$7.56B | n/a | 25,303× | 3.4× | n/a | n/a | n/a | 0.70 |
| Larimar Therapeutics, Inc. · NASDAQ:LRMR | US$328.6M | US$204.7M | n/a | n/a | n/a | 3.2× | n/a | 0.1× | 1.48 |
| CytoDyn Inc. · OTC:CYDY | US$326.4M | US$345.8M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| C4 Therapeutics, Inc. · NASDAQ:CCCC | US$325.7M | US$175.5M | n/a | 5.4× | n/a | 1.4× | −282.2% | 0.2× | 1.46 |
| Laekna, Inc. · HKEX:2105 | US$322.8M | US$154.3M | n/a | 9.6× | n/a | 1.8× | −214.9% | 0.0× | n/a |
| Foresee Pharmaceuticals Co., Ltd. · TPEX:6576 | US$319.8M | US$303.4M | 469× | 21.2× | n/a | 8.3× | 4.8% | 0.3× | n/a |
| GI Innovation, Inc. · KRX:358570 | US$315.9M | US$286.8M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | n/a |
| MapLight Therapeutics, Inc. · NASDAQ:MPLT | US$313.9M | US$29.84M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.28 |
| Median of the others | US$326.0M | US$245.7M | 469× | 1,151× | 3.4× | 2.5× | −214.9% | 0.1× | 1.37 |
Forecasts
2 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.99 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jean-Pierre Sommadossi | Chairman & CEO, Atea Pharmaceuticals |
| Andrea Corcoran | CFO & Executive VP, Legal |
| Shari Noble | VP, Deputy General Counsel |
| Atea Pharmaceuticals | website at ir.ateapharma.com |
| Jonae Barnes | Senior VP, Investor Relations & Corporate Communications |
| Jonae BarnesSVP | Investor Relations and Corporate |
| Adam DeZure | Senior VP, Clinical Development |
| Adel Moussa | EXECUTIVE VP, CHEMISTRY |
| Brian Rowe | VP, Business Development |
| Bruce Belanger | Senior VP, Biostatistics |
| James MB Evans | SENIOR VP, CMC Manufacturing |
| Jayanthi Wolf | Executive VP, Regulatory Affairs |
| Keith Pietropaolo | Executive VP, Clinical Sciences and Project Management |
| Laura Ishak | Senior VP, Clinical Operations |
| Marc Van Hulle | VP, Finance |
| Nancy Agrawal | Executive VP, Preclinical Development |
| Qi Huang | Senior VP, Virology |
| Wayne Foster | EXECUTIVE VP, Chief Accounting Officer |
| Xiao-Jian Zhou | EXECUTIVE VP, EARLY STAGE DEVELOPMENT |
| Arantxa Horga | Chief Medical Officer |
| Janet Hammond | CHIEF DEVELOPMENT OFFICER |
| John Vavricka | CHIEF COMMERCIAL OFFICER |
| Polly A. Murphy | Chief Business Officer, Urogen Pharma |
Board
| Director | Role |
|---|---|
| Jean-Pierre Sommadossi | Chairman & CEO, Atea Pharmaceuticals |
| Barbara Duncan | Director |
| Howard Berman | Director |
| Polly A. Murphy | Chief Business Officer, Urogen Pharma |
Events
- Next results
- Mar 4, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q1 2026 Earnings Call | Tue, May 12, 2026 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q4 2025 Earnings Call | Thu, Mar 05, 2026 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q3 2025 Earnings Call | Wed, Nov 12, 2025 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q4 2024 Earnings Call | Thu, Mar 06, 2025 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q1 2024 Earnings Call | Tue, May 14, 2024 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q4 2023 Earnings Call | Wed, Feb 28, 2024 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q3 2023 Earnings Call | Wed, Nov 08, 2023 · 4:30 PM ET | Replay |
All 19 calls
| Call | When | Status |
|---|---|---|
| Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2023 Earnings Call | Tue, Aug 08, 2023 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q1 2023 Earnings Call | Mon, May 08, 2023 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q4 2022 Earnings Call | Tue, Feb 28, 2023 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q3 2022 Earnings Call | Mon, Nov 07, 2022 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2022 Earnings Call | Mon, Aug 08, 2022 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q4 2021 Earnings Call | Mon, Feb 28, 2022 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q3 2021 Earnings Call | Thu, Nov 11, 2021 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2021 Earnings Call | Thu, Aug 12, 2021 · 4:30 PM ET | Replay |
| Atea Pharmaceuticals (NASDAQ:AVIR) Q1 2021 Earnings Call | Thu, May 13, 2021 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | −4.8% |
| Q2 2026 | Aug 12, 2026 · After close | +0.2% |
| Q1 2026 | May 13, 2026 | −22.4% |
| Q4 2025 | Mar 5, 2026 · After close | +11.1% |
| Q3 2025 | Nov 12, 2025 · After close | −12.6% |
| Q2 2025 | Aug 7, 2025 · After close | −2.3% |
| Q1 2025 | May 12, 2025 · After close | −11.2% |
| Q4 2024 | Feb 26, 2025 · After close | −3.2% |
| Q3 2024 | Nov 7, 2024 · After close | +1.7% |
| Q2 2024 | Aug 7, 2024 · After close | +7.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | −6.3% |
| Q4 2023 | Feb 28, 2024 · After close | −1.4% |
| Q3 2023 | Nov 8, 2023 · After close | −9.1% |
| Q2 2023 | Aug 8, 2023 · After close | +3.8% |
| Q1 2023 | May 8, 2023 · After close | −2.6% |
| Q4 2022 | Feb 28, 2023 · After close | −8.2% |
| Q3 2022 | Nov 7, 2022 · After close | −9.9% |
| Q2 2022 | Aug 8, 2022 · After close | −1.3% |
| Q1 2022 | May 10, 2022 · Before open | +9.9% |
| Q4 2021 | Feb 28, 2022 · After close | +1.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 31 slides | Aug 12, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 29 slides | May 12, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 28 slides | Mar 5, 2026 |
| 44th Annual J.P. Morgan Healthcare Conference (January 2026) | Conference | 25 slides | Jan 15, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 27 slides | Nov 12, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 26 slides | Aug 7, 2025 |
| FY2024 Earnings Presentation | Earnings | 23 slides | Mar 6, 2025 |
| 43rd Annual J.P. Morgan Healthcare Conference (January 2025) | Conference | 22 slides | January 2025 |
| Q3 2024 Earnings Presentation | Earnings | 18 slides | Nov 7, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 30 slides | Aug 7, 2024 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| JP Morgan Healthcare Conference 2022 | Conference | 28 slides | Jan 10, 2022 |
| Q1 2021 Earnings Presentation | Earnings | 17 slides | May 13, 2021 |
IPO
Priced at US$24.00 a share on Oct 29, 2020.
- Price
- US$24.00 a share
- Shares offered
- 12,500,000 shares of common stock
- Offering size
- US$300 million
- Underwriters' option
- Up to 1,875,000 more shares
- Underwriters
- J.P. Morgan, Morgan Stanley, Evercore ISI, William Blair · In the order on the cover
- Shares delivered
- On or about Nov 3, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 19, 2020 |
| Filed publicly | Oct 9, 2020 |
| Amended twice | Newest Oct 26, 2020 |
| Shares registered with an exchange | Oct 26, 2020 |
| Declared effective by the SEC | Oct 29, 2020 |
| Final prospectus, with the price | Oct 30, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 30, 2020 |
| EFFECT · Notice that a registration is effective | Oct 29, 2020 |
| S-1MEF · Registration of more shares for the same offering | Oct 29, 2020 |
| CORRESP · Letter to the SEC | Oct 29, 2020 |
| CERT · Exchange's certificate of listing | Oct 28, 2020 |
| CORRESP · Letter to the SEC | Oct 27, 2020 |
| CORRESP · Letter to the SEC | Oct 27, 2020 |
| UPLOAD · Letter from the SEC | Oct 27, 2020 |
| S-1/A · Registration statement, amended | Oct 26, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 26, 2020 |
All 16 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Oct 23, 2020 |
| S-1 · Registration statement | Oct 9, 2020 |
| DRSLTR · Letter to the SEC with a draft | Aug 7, 2020 |
| DRS/A · Draft registration statement, amended | Aug 7, 2020 |
| UPLOAD · Letter from the SEC | Jul 16, 2020 |
| DRS · Draft registration statement | Jun 19, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 30, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 192.2M | 351.4M | 48.6M | 0 | 0 |
| Cost of revenue | 416.0K | 83.4M | 70.1M | 260.0K | 29.0K | 38.0M | 17.0K | 17.0K |
| Gross profit | -416.0K | -83.4M | -70.1M | -260.0K | 351.4M | 10.6M | -17.0K | -17.0K |
| Research and development | 148.0M | 144.1M | 114.2M | 81.9M | 167.2M | 38.0M | 10.2M | 6.67M |
| Selling, general and administrative | 32.9M | 48.8M | 49.9M | 48.7M | 45.8M | 21.6M | 4.44M | 2.80M |
| Operating income | -180.9M | -192.9M | -164.2M | -130.7M | 138.4M | -11.0M | -14.6M | -9.48M |
| Depreciation and amortization | 416.0K | 416.0K | 416.0K | 260.0K | 29.0K | 19.0K | 17.0K | 17.0K |
| EBITDA | -180.5M | -192.5M | -163.7M | -130.4M | 138.4M | -11.0M | -14.6M | -9.46M |
| Interest expense | 11.2M | 242.0K | 83.0K | 0 | 0 | |||
| Income before tax | -164.5M | -167.5M | -134.9M | -119.5M | 138.6M | -10.9M | -14.0M | -9.06M |
| Income tax | -6.16M | 925.0K | 1.02M | -3.59M | 17.4M | -83.0K | -574.0K | 413.0K |
| Net income | -158.3M | -168.4M | -136.0M | -115.9M | 121.2M | -10.9M | -14.0M | -9.06M |
| Earnings per share, basic | -1.94 | -2.00 | -1.63 | -1.39 | 1.46 | -0.51 | -1.39 | -0.90 |
| Earnings per share, diluted | -1.94 | -2.00 | -1.63 | -1.39 | 1.37 | -0.51 | -1.39 | -0.90 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 95.7M | 64.7M | 143.8M | 188.5M | 764.4M | 850.1M | 21.7M | 34.5M |
| Short-term investments | 206.1M | 390.0M | 434.3M | 458.2M | 0 | |||
| Receivables | 5.82M | |||||||
| Current assets | 311.0M | 462.4M | 590.5M | 660.9M | 772.4M | 863.5M | 21.9M | 34.7M |
| Property, plant and equipment | 457.0K | 873.0K | 1.29M | 1.71M | 23.0K | 48.0K | 41.0K | 56.0K |
| Total assets | 315.2M | 464.7M | 595.0M | 666.7M | 772.9M | 863.6M | 22.1M | 34.9M |
| Accounts payable | 12.9M | 4.46M | 4.25M | 2.55M | 4.53M | 60.0K | 548.0K | 391.0K |
| Current liabilities | 39.8M | 18.6M | 32.4M | 18.5M | 56.9M | 315.8M | 2.44M | 1.76M |
| Total debt | 843.0K | 1.64M | 2.40M | 3.12M | 197.0K | |||
| Total liabilities | 39.8M | 25.8M | 39.8M | 26.1M | 62.8M | 315.8M | 2.53M | 71.0M |
| Shareholders' equity | 275.4M | 438.9M | 555.2M | 640.6M | 710.1M | 547.8M | -49.6M | -36.2M |
| Shares outstanding | 78.1M | 84.5M | 83.4M | 83.3M | 83.1M | 82.4M | 10.1M | 83.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -132.0M | -135.5M | -85.4M | -121.0M | -87.0M | 296.7M | -12.8M | -7.91M |
| Capital spending | 0 | 0 | 0 | -1.94M | -4.00K | -26.0K | -2.00K | -12.0K |
| Free cash flow | -132.0M | -135.5M | -85.4M | -122.9M | -87.0M | 296.7M | -12.8M | -7.92M |
| Cash from investing | 188.8M | 56.1M | 40.3M | -455.4M | -4.00K | -26.0K | -2.00K | -12.0K |
| Cash from financing | -25.7M | 267.0K | 257.0K | 370.0K | 1.47M | 531.7M | -15.0K | 27.5M |
| Share buybacks | -25.5M | 0 | 1.47M | 531.7M | ||||
| Change in cash | 31.0M | -79.1M | -44.8M | -576.0M | -85.5M | 828.5M | -12.8M | 19.6M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 8-K · Current report | Nov 9, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 22, 2026 | Meeting outcome | SEC |
| 4/A · Change in ownership, amended | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 5, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Aug 7, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 23, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 17, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 3, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 1, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 1, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Mar 26, 2025 | Meeting notice | SEC |
| DFAN14A | Mar 26, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Mar 24, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 24, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 21, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 6, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2025 | Results | SEC |
| SCHEDULE 13D · Big-stake notice | Mar 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 24, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| SCHEDULE 13D · Big-stake notice | Dec 16, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 10, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Nov 20, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 15, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 15, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Nov 14, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| S-3 · Registration statement | Nov 7, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 4 · Change in ownership | Sep 19, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 19, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 17, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 21, 2024 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | Jun 20, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 5, 2024 | Other filings | SEC |
| DEFA14A · Additional proxy material | Jun 4, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 10-K · Annual report | Feb 28, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 28, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 15, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 15, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 7, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 1, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 24, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 28, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2023 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 7, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 2, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Sep 11, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2023 | Results | SEC |
| 8-K · Current report | Jun 21, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Jun 12, 2023 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | May 25, 2023 | Meeting notice | SEC |
| SC 13D · Big-stake notice | May 22, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2023 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 10-K · Annual report | Feb 28, 2023 | Annual report | SEC |
| 8-K · Current report | Feb 28, 2023 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 24, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 15, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2022 | Results | SEC |
| 4 · Change in ownership | Jun 21, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2022 | Insider trade | SEC |
| 8-K · Current report | Jun 21, 2022 | Meeting outcome | SEC |
This page holds 200 of 326 filings. Open Filings
Cap table
Built by 6ix from Atea Pharmaceuticals, Inc.’s releases · as of Aug 10, 2026
- Common shares
- 80,204,699
- Fully diluted
- 80,204,699
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 80,204,699 | Aug 10, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Aug 10, 2026 | 80,204,699 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Franklin Berger Other companies: Retension Pharmaceuticals, Inc. (Director · Since at least Oct 13, 2026); ESSA Pharma Inc (Director · Since at least Oct 1, 2020); Kezar Life Sciences, Inc. (Director · Since at least Jun 25, 2019); Rain Oncology Inc (Director · Apr 22, 2021 – Jan 26, 2024 · Past); Kineta Inc. (Director · Jun 27, 2019 – Jun 29, 2020 · Past); Atreca Inc (Director · Jun 19, 2019 – Jun 13, 2023 · Past); Five Prime Therapeutics Inc (Director · Jun 10, 2019 – Apr 16, 2021 · Past); Tocagen Inc (Director · May 29, 2019 – Oct 4, 2019 · Past); Immune Design Corp (Director · Apr 2, 2019 – Apr 2, 2019 · Past) | Director · Since at least Oct 29, 2020 |
| Andrew A F Hack Other companies: Mersana Therapeutics Inc (Director · Since at least Jun 27, 2017); Nuvalent, Inc. (Director · Jul 28, 2021 – Dec 11, 2024 · Past); BCLS Acquisition Corp (Chief Financial Officer, Director · Oct 21, 2020 – Oct 26, 2020 · Past); Dynavax Technologies Corporation (Director · Aug 12, 2019 – Aug 8, 2023 · Past); Allena Pharmaceuticals Inc (Director · Jun 8, 2018 – Nov 17, 2020 · Past); Editas Medicine, Inc. (Chief Financial Officer · Feb 2, 2016 – Feb 4, 2019 · Past) | Director · Oct 29, 2020 – Nov 3, 2020 · Past |
| Arthur Kirsch Other companies: Evommune, Inc. (Audit · Since at least Nov 5, 2025); Liquidia Corporation (Board Member · Since at least Mar 24, 2021); Kadmon Holdings Inc (Director · May 15, 2019 – Nov 9, 2021 · Past); Aralez Pharmaceuticals Inc (Director · May 12, 2016 – Dec 8, 2017 · Past) | Director · Since at least Feb 20, 2025 |
| Barbara Duncan Other companies: Halozyme Therapeutics, Inc. (Director · Since at least Apr 25, 2024); Ovid Therapeutics Inc. (Director · Since at least Feb 22, 2024); Fusion Pharmaceuticals Inc (Director · Jun 4, 2024 – Jun 4, 2024 · Past) | Director · Since at least Jun 16, 2024 |
| Jean-Pierre Sommadossi Other companies: ABG Acquisition I Corp (Director · Feb 16, 2021 – Mar 1, 2023 · Past); Kezar Life Sciences, Inc. (Director · Jun 20, 2018 – Jun 28, 2021 · Past); Idenix Pharmaceuticals Inc (President, CEO, Chairman, Director · Dec 31, 2005 – Feb 10, 2010 · Past) | Chairman & CEO, Atea Pharmaceuticals · Since at least Oct 29, 2020 |
| Bruce Polsky Other companies: Cogentix Medical Inc (Director · Jul 26, 2012 – Aug 26, 2013 · Past) | Director · Since at least Oct 29, 2020 |
| Howard Berman Other companies: Coya Therapeutics, Inc. (Executive Chairman, Director · Since at least Dec 28, 2022) | Director · Since at least Apr 17, 2025 |
| Polly A. Murphy Other companies: Celcuity Inc. (Director · Since at least Jun 24, 2024) | Director · Since at least Mar 26, 2025 |
| Wayne Foster Other companies: Mersana Therapeutics Inc (Vice President of Finance · Jun 27, 2017 – Jan 23, 2019 · Past) | EXECUTIVE VP, Chief Accounting Officer · Since at least Oct 29, 2020 |
| Adam DeZure | Senior VP, Clinical Development · Since at least Nov 5, 2026 |
All 32 people
| Person | Seat |
|---|---|
| Adel Moussa | EXECUTIVE VP, CHEMISTRY · Since at least Nov 5, 2026 |
| Andrea Corcoran | CFO & Executive VP, Legal · Since at least Oct 29, 2020 |
| Arantxa Horga | Chief Medical Officer · Since at least Mar 26, 2025 |
| Atea Pharmaceuticals | website at ir.ateapharma.com · Since at least Aug 5, 2026 |
| Brian Rowe | VP, Business Development · Since at least Nov 5, 2026 |
| Bruce Belanger | Senior VP, Biostatistics · Since at least Nov 5, 2026 |
| Bruno Lucidi | Director · Since at least Oct 29, 2020 |
| James MB Evans | SENIOR VP, CMC Manufacturing · Since at least Nov 5, 2026 |
| Janet Hammond | CHIEF DEVELOPMENT OFFICER · Since at least Oct 29, 2020 |
| Jayanthi Wolf | Executive VP, Regulatory Affairs · Since at least Nov 5, 2026 |
| Jerome M Adams | Director · Since at least Jun 20, 2025 |
| John Vavricka | Chief Commercial Officer · Since at least Oct 29, 2020 |
| Jonae Barnes | Senior VP, Investor Relations & Corporate Communications · Since at least Nov 2, 2026 |
| Jonae BarnesSVP | Investor Relations and Corporate · Since at least Jul 28, 2026 |
| Keith Pietropaolo | Executive VP, Clinical Sciences and Project Management · Since at least Nov 5, 2026 |
| Laura Ishak | Senior VP, Clinical Operations · Since at least Nov 5, 2026 |
| Marc Van Hulle | VP, Finance · Since at least Nov 5, 2026 |
| Maria Arantxa Horga | Chief Medical Officer · Since at least Jan 31, 2023 |
| Nancy Agrawal | Executive VP, Preclinical Development · Since at least Nov 5, 2026 |
| Qi Huang | Senior VP, Virology · Since at least May 13, 2026 |
| Shari Noble | VP, Deputy General Counsel · Since at least Nov 5, 2026 |
| Xiao-Jian Zhou | EXECUTIVE VP, EARLY STAGE DEVELOPMENT · Since at least May 13, 2026 |
Log in to ask 6ix AI your own questions about Atea Pharmaceuticals, Inc.